Surface Oncology Inc (NASDAQ:SURF) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 644,100 shares, a growth of 86.3% from the May 30th total of 345,800 shares. Based on an average daily trading volume, of 72,200 shares, the short-interest ratio is presently 8.9 days. Currently, 5.9% of the shares of the company are sold short.
NASDAQ:SURF traded down $0.01 during trading hours on Thursday, hitting $2.53. 19,625 shares of the company were exchanged, compared to its average volume of 69,499. The stock has a market cap of $70.45 million, a PE ratio of -7.67 and a beta of 2.42. Surface Oncology has a 52-week low of $2.47 and a 52-week high of $17.24. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.28 and a quick ratio of 11.28. The company’s 50 day moving average is $3.28.
Surface Oncology (NASDAQ:SURF) last released its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.31. Surface Oncology had a negative net margin of 148.15% and a negative return on equity of 38.97%. The company had revenue of $14.43 million for the quarter, compared to the consensus estimate of $2.50 million. As a group, equities research analysts predict that Surface Oncology will post -1.97 EPS for the current year.
A number of equities research analysts have weighed in on the stock. Cowen restated a “hold” rating on shares of PDL BioPharma in a report on Thursday, May 9th. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Zacks Investment Research cut shares of Haynes International from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.
Featured Article: Cash Flow
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.